Under the aegis of - MSDA Congress · W.S.Harris (USA) N.Marx (Germany) R.Ross (Canada) BUFFET LUNCH FONDATION CŒUR ET ARTÈRES SYMPOSIUM 2 Physical activity and cardiometabolic

Under the aegis of

Gold sponsor

Silver sponsors

Bronze sponsors

Sponsors

The scientific

committee and the

organizing secretariat

thank warmly the

following actors of the

pharmaceutical

industry for their

support and

contribution to the

4th Metabolic

Syndrome, type II

Diabetes and

Atherosclerosis

congress.

2

/

Metabolic Syndrome, type ll Diabetesand Atherosclerosis congress4th

C O N T E N T S

Welcome address ........................................................................................................................................................ 4

Scientific and organizing committee .............................................................................................. 4

Exhibition map ............................................................................................................................................................... 5

Program at a glance ................................................................................................................................................ 6

DETAILED PROGRAM

Thursday May 17th, 2007

morning ........................................................................................................................................................................ 8

afternoon ................................................................................................................................................................ 10

Friday May 18th, 2007

morning .................................................................................................................................................................... 12

afternoon ................................................................................................................................................................ 14

Saturday May 19th, 2007

morning .................................................................................................................................................................... 15

afternoon ................................................................................................................................................................ 15

LIST OF POSTER ABSTRACTS ............................................................................................................ 18

Information to the faculty and poster authors ............................................................ 20

General information ............................................................................................................................................ 22

The congress from A to Z .............................................................................................................................. 24

3

Welcome address

Dear Friends and Colleagues,

On behalf of the Scientific Committee of the 4th “Metabolic Syndrome,

type II Diabetes and Atherosclerosis congress”, it is our great pleasure

to cordially welcome all the participants to the Lisbon Congress Centre.

We have made every effort to set up a program highly susceptible to interest both

physicians and academic researchers, covering the most recent data on the topics of this

congress.

We hope that you will enjoy the scientific events of this congress. We would like to thank

the high-level lecturers and all the authors who submitted very interesting papers and

posters. To give more opportunities to share our knowledge, posters will be displayed for

the whole duration of the meeting.

Our wishes are that you can enjoy and never forget this exciting scientific event.

Welcome to Lisbon,

Professor Jean-Charles FRUCHART

Chair

SCIENTIFIC AND ORGANIZING COMMITTEE

Chair:

Pr Jean-Charles FRUCHART (France)

Atherosclerosis Department

and UR 545 Inserm

Institut Pasteur de Lille

1, rue du Professeur Calmette

59019 Lille Cedex

France

Tel: +33 (0)3 20 87 73 56

Fax: +33 (0)3 20 87 73 19 or 60

Members:

Dr Jamila FRUCHART-NAJIB

Pr Patrick DURIEZ

Pr Bart STAELS

4

5


Exhibition map

OPENING TIMES OF THE EXHIBITION

Wednesday May 16th 04.00 p.m. - 07.00 p.m.

Thursday May 17th 08.30 a.m. - 06.00 p.m.

Friday May 18th 08.30 a.m. - 06.00 p.m.

Saturday May 19th 08.30 a.m. - 05.00 p.m.

to the Foyer C

(Congress welcome desk)

to the Pavilion 5

(Lunch area)

to the

Auditorium 1

(Academic sessions,

symposia and

lunch debates)

PAVILION 4

(level 1)

(Welcome cocktail on May 16)

6


WEDNESDAY MAY 16

CONGRESS OPENING CEREMONYAuditorium 1, level 1

Lisbon Congress Centre

WELCOME COCKTAILRestaurant ESPAÇO TEJO, level 1

Lisbon Congress Centre

THURSDAY MAY 17

ACADEMIC SESSION 1Obesity, metabolic syndrome

and type II diabetes:still growing epidemicsCo-Chairs: B. Brewer (USA)

C. Calvo (Chile)G.Crepaldi (Italy)

F.Sacks (USA)C. Calvo (Chile)

L.Tokgozoglu (Turkey)

COFFEE BREAK AND POSTER VIEWING

SYMPOSIUM SOLVAY

Metabolic bomb is ticking;how can we defuse it?

Chair: F. Sacks (USA)S. Smith (USA)

R. Ceska (Czech Republic)P. Dodson (UK)

A. Zambon (Italy)

LUNCH DEBATE ASTRAZENECA

Dyslipidemia and atherosclerosis:

dangerous liaisons ...Co-Chairs: J.-C. Fruchart (France)

J. Shepherd (UK)J. Chapman (France)S. Kownator (France)

J. Shepherd (UK)

ACADEMIC SESSION 2Metabolic abnormalities

associated with metabolic syndrome and diabetes

Co-Chairs: R.Ceska (Czech Republic)A. Catapano (Italy)

B. Brewer (USA)M. Lafontan (France)K. Clément (France)


SYMPOSIUM MSD / SCHERING-PLOUGH

Diabetic dyslipidemia:therapeutic associations’

interestChair: J.-M. Lablanche (France)

E. Bruckert (France)M. Krempf (France)

J.-C. Fruchart (France)

FRIDAY MAY 18

ACADEMIC SESSION 3JOINT SESSION SUPPORTED BY THE IAS

Diagnosis and preventionChair: S. Smith (USA)

P. Barter (Australia)V. Brown (USA)

J. Davignon (Canada)


SYMPOSIUM BAYER

In may 2007, are hypertensive patients with

metabolic syndrome still different from otherhypertensive patients?

Chair: G. Assman (Germany)A. Benetos (France)

G. Assmann (Germany)M.-C. Aumont (France)

BUFFET LUNCH

ACADEMIC SESSION 4Current and future

treatment strategies in cardiometabolic

complicationsCo-Chairs: G. Crepaldi (Italy)

M. Komajda ( France)M. Komajda (France)

B. Staels (France)J. Plutzky (USA)


SYMPOSIUM NOVARTIS

Management of high risk patients

Chair: E. Bruckert (France)E. Bruckert (France)

J.-M. Lablanche (France)T. Laperche (France)

J. Amar (France)

SATURDAY MAY 19

FONDATION CŒUR ET ARTÈRES

SYMPOSIUM 1Nutrition and

cardiometabolic / cardiovascular disease risksCo-Chairs: J.M. Silva (Portugal)

G. Schwartz (USA)A.Tremblay (Canada)

W. S. Harris (USA)N. Marx (Germany)

R. Ross (Canada)

BUFFET LUNCH

FONDATION CŒUR ET ARTÈRES

SYMPOSIUM 2Physical activity and

cardiometabolic / cardiovascular disease risksChair: A. Tremblay (Canada)

P. A. McCullough (USA)J. Gill (UK)

C. Simon (France)

PPARS WHITE PAPER

(Private session)

SUNDAY MAY 20

DISCUSSED POSTER SESSION

Chair: J.-C. Fruchart (France)

End of the Congress

09.00 - 10.30 a.m.

02.00 - 06.00 p.m.

02.00 - 04.00 p.m.

12.00 - 02.00 p.m.

09.20 a.m. - 12.00 p.m.

04.00 - 05.30 p.m.

02.00 - 03.30 p.m.

12.30 - 02.00 p.m.

11.00 a.m. - 12.30 p.m.

09.00 - 10.30 a.m.

04.15 - 05.45 p.m.

02.15 - 03.45 p.m.

12.45 - 02.15 p.m.

10.45 a.m. - 12.30 p.m.

08.35 - 10.15 a.m.

07.30 - 09.00 p.m.

07.00 - 07.30 p.m.

Program at a glance(All scientific sessions will be held in the auditorium 1, level 1)

7

DETAILED PROGRAM


AUDITORIUM I

Wednesday May 16, 2007 / Evening

07.00 p.m. CONGRESS OPENING CEREMONY

07.30 p.m. J.-C. Fruchart

07.30 p.m. WELCOME COCKTAIL

09.00 p.m. Lisbon Congress Centre - restaurant “Espaço Tejo”, level 1

AUDITORIUM I

Thursday May 17, 2007 / Morning

08.35 a.m. ACADEMIC SESSION 1

10.15 a.m. Obesity, metabolic syndrome and type II diabetes: still growing epidemicsChaired by: B. Brewer (USA) - C. Calvo (Chile)

08.35 a.m. Components of the metabolic syndrome and incidence of diabetes in elderly Italians:

the Italian Longitudinal Study on Aging ...................................................................................... G. Crepaldi (Italy)

09.00 a.m. Atherogenic lipoprotein targets for diet and drug treatment ............................................. F. Sacks (USA)

09.25 a.m. Vascular inflammation and endothelial dysfunction in adults and adolescents

with metabolic syndrome ............................................................................................................................. C. Calvo (Chile)

09.50 a.m. Cardiovascular complications in diabetes & metabolic syndrome:

What do the new guidelines tell us? .................................................................................. L.Tokgozoglu (Turkey)

10.15 a.m. Coffee Break - Visit of the exhibition and poster areas (Pavilion 4, level 1)

10.45 a.m. ..........................................................................................................

10.45 a.m. SYMPOSIUM SPONSORED BY SOLVAY PHARMACEUTICALS

12.30 p.m. Metabolic bomb is ticking; how can we defuse it?Chaired by: F. Sacks (USA)

10.45 a.m. Global epidemiology, risks and consequences of the metabolic syndrome .......... S. Smith (USA)

11.10 a.m. Prediabetes, the metabolic syndrome and cardiovascular disease ..... R. Ceska (Czech Republic)

11.35 a.m. Early detection and prevention of retinopathy .............................................................................. P. Dodson (UK)

12.00 p.m. Therapeutical approaches of macro and micro-vascular events .............................. A. Zambon (Italy)

AL-04

AL-03

AL-02

AL-01

8

M A N A G E M E N T O F H Y P E R T E N S I O N A N D M O R E

For more information see: www.solvay.com

MOrbidity and mortality after Stroke – Eprosartan compared with nitrendipine for Secondary preventionSTROKE 2005; 36: 1218-1226


Thursday May 17, 2007 / Afternoon

12.45 p.m. LUNCH DEBATE SPONSORED BY ASTRAZENECA

02.15 p.m. Dyslipidemia and atherosclerosis: dangerous liaisons …Chaired by: J.-C. Fruchart (France) - J. Shepherd (UK)

Atherosclerosis progression versus regression : role of LDL ....................... J. Chapman (France)

Best practice in vascular imaging ............................................................. S. Kownator (France)

Current therapeutic strategies for dyslipidemia .............................................. J. Shepherd (UK)

02.15 p.m. ACADEMIC SESSION 2

03.45 p.m. Metabolic abnormalities associated with metabolic syndrome and diabetesChaired by: R. Ceska (Czech Republic) - A. Catapano (Italy)

02.15 p.m. The role of HDL in the treatment of patients with

the metabolic syndrome and diabetes ............................................................................................. B. Brewer (USA)

02.45 p.m. Atrial natriuretic peptide: the control of lipolysis, adipokine

and cytokines production in human subcutaneous adipose tissue .............. M. Lafontan (France)

03.15 p.m. Adipose tissue, inflammation and metabolic diseases ................................................ K. Clément (France)

03.45 p.m. Coffee Break - Visit of the exhibition and poster areas (Pavilion 4, level 1)

04.15 p.m.

04.15 p.m. SYMPOSIUM SPONSORED BY MSD / SCHERING-PLOUGH

05.45 p.m. Diabetic dyslipidemia: therapeutic associations’ interestChaired by: J.-M. Lablanche (France)

04.15 p.m. Diabetic patients’ treatment and NSFA recommendations ...................................... E. Bruckert (France)

04.45 p.m. Cholesterol absorption and production: mechanistic aspects ................................ M. Krempf (France)

05.15 p.m. Intensive LDL-c lowering in patients with diabetes ............................................... J.-C. Fruchart (France)

AL-07

AL-06

AL-05

AUDITORIUM I

10

EZETROL® 10 mg, comprimé. PRESENTATION ET COMPOSITION (*) : ézétimibe (10 mg) ; croscarmellose sodique, lactose monohydraté, stéarate de magnésium, cellulose microcristalline, povidone (K29-32), laurylsulfate de sodium. INDICATIONS :

– Hypercholestérolémie primaire : • EZETROL en association avec une statine (inhibiteur de l’HMG-CoA réductase) est indiqué comme traitement adjuvant au régime chez les patients ayant une hypercholestérolémie primaire (familialehétérozygote et non familiale) et qui ne sont pas contrôlés de façon appropriée par une statine seule. • EZETROL en monothérapie est indiqué comme traitement adjuvant au régime chez les patients ayant une hypercholestérolémie primaire(familiale hétérozygote et non familiale) pour lesquels un traitement par statine est inapproprié ou est mal toléré. – Hypercholestérolémie familiale homozygote (HFHo) : • EZETROL en association avec une statine est indiqué commetraitement adjuvant au régime chez les patients ayant une HFHo. Ces patients peuvent recevoir également des traitements adjuvants (exemple : aphérèse des LDL). – Sitostérolémie homozygote (phytostérolémie) : • EZETROL est indiquécomme traitement adjuvant au régime, chez les patients ayant une sitostérolémie familiale homozygote. – Des études démontrant l’efficacité d’EZETROL dans la prévention des complications de l’athérosclérose ne sont pas encore terminées.POSOLOGIE ET MODE D’ADMINISTRATION (*) : • Suivre un régime hypolipidémiant adapté pendant toute la durée du traitement. • Prendre un comprimé par jour. • En association à une statine, poursuivre la posologie de la statine utilisée(cf. RCP de la statine utilisée). • En association à une résine échangeuse d’ions, prendre EZETROL soit ≥ 2 heures avant ou ≥ 4 heures après celle-ci. • Enfants et adolescents ≥ 10 ans : pas d’ajustement posologique mais expérience cliniquelimitée. • Enfants < 10 ans : non recommandé. • Sujet âgé/insuffisant hépatique léger/insuffisant rénal : pas d’ajustement posologique. C.T.J. : 1,61 €. CONTRE-INDICATIONS : – Hypersensibilité à la substance active ou à l’un des constituantsdu médicament. – En association avec une statine : • Se référer au Résumé des Caractéristiques du Produit de la statine utilisée. • Le traitement par EZETROL est contre-indiqué pendant la grossesse ou l’allaitement. • Le traitement parEZETROL est contre-indiqué chez les patients présentant une affection hépatique évolutive ou des élévations persistantes et inexpliquées des transaminases plasmatiques. MISES EN GARDE SPECIALES ET PRECAUTIONS PARTICULIERES

D’EMPLOI (*) : – Des cas d’atteinte musculaire et de rhabdomyolyse ont été rapportés. Les patients doivent être informés du risque d’atteinte musculaire. – Si associé à une statine, pratiquer des tests hépatiques en début de traitement etselon la recommandation pour la statine. – Non recommandé en cas d’insuffisance hépatique modérée ou sévère ou de prise de fibrates. – Prudence en cas de prise de ciclosporine, de warfarine ou d’autres AVK. – En raison de la présencede lactose, ce médicament est contre-indiqué en cas de galactosémie congénitale, de syndrome de malabsorption du glucose et du galactose ou de déficit en lactase. INTERACTIONS AVEC D’AUTRES MEDICAMENTS ET AUTRES FORMES

D’INTERACTION (*) : – Association non recommandée avec les fibrates. – Interaction avec la cholestyramine, la ciclosporine et la warfarine. GROSSESSE ET ALLAITEMENT (*) : – Contre-indiqué en association avec une statine. Ne pasadministrer EZETROL à la femme enceinte (sauf en cas de nécessité absolue) ou allaitante. EFFETS INDESIRABLES (*) : Etudes cliniques : – EZETROL administré seul : • Fréquent : céphalées ; douleurs abdominales, diarrhée. – EZETROLassocié à une statine : • Fréquent : céphalées, fatigue ; douleurs abdominales, constipation, diarrhée, flatulence, nausées ; myalgies. – Biologie : augmentation des transaminases et des CPK. – Depuis la mise sur le marché : • rare :hypersensibilité incluant rash, urticaire ; nausées ; hépatite ; arthralgies, myalgies ; augmentation des transaminases et augmentation des CPK. • très rare : thrombopénie ; anaphylaxie, angio-œdème ; pancréatite ; lithiase biliaire, cholécystite ;myopathie/rhabdomyolyse. PROPRIETES PHARMACOLOGIQUES (*) : Classe pharmacothérapeutique : autres réducteurs du cholestérol et des triglycérides. DONNEES ADMINISTRATIVES : Liste I • A.M.M. 362 270-7 : boîte de 28 cps ;(2003, rév. 06.09.06). Prix : 45,11 €. Remb. Séc. Soc. 65%. – Agréé Collect. • A.M.M. 564 349-3 : boîte de 50 cps ; (2003, rév. 06.09.06) ; Conditionnement exclusivement hospitalier. – Agréé Collect. TITULAIRE DE L’A.M.M. : MSD-SP LTD – Hertford Road, Hoddesdon – HERTFORDSHIRE EN11 9BU – Royaume-Uni. EXPLOITANT : Laboratoires MERCK SHARP & DOHME-CHIBRET – 3, avenue Hoche – 75114 PARIS cedex 08 – Tél. 01 47 54 87 00 – Centre d’Information : Tél. 01 47 54 88 00. *Pour une information complète, consulter le dictionnaire VIDAL.Cette spécialité fait l’objet d’une co-promotion des Laboratoires MERCK SHARP & DOHME-CHIBRET et SCHERING-PLOUGH.

Schering-Plough* Plus forts ensemble !

Hypercholestérolémie primaire non contrôlée par une statine seule et le régime

1007

EZT

06F

0286

J -

Octo

bre

2006

1er inhibiteurde l’absorption

intestinaledu cholestérol

Synthèsehépatique

Agir sur deuxsources du cholestérol

pour plus d’efficacité

® Marque déposée de MSP Singapore Company, LLC

Pour plus d’informations, veuillez consulter le RCP disponible sur le site www.msd-france.com


Friday May 18, 2007 / Morning

09.00 a.m. ACADEMIC SESSION 3

10.30 a.m. JOINT SESSION SUPORTED BY THE INTERNATIONAL ATHEROSCLEROSIS SOCIETY (I.A.S.)

Diagnosis and preventionChaired by: S. Smith (USA)

09.00 a.m. Importance of dyslipidemia in the diagnosis of the metabolic syndrome .... P. Barter (Australia)

09.30 a.m. Do we have the right lipid targets in preventing vascular disease

in the metabolic syndrome? ....................................................................................................................... V. Brown (USA)

10.00 a.m. The metabolic syndrome is not going away ................................................................... J. Davignon (Canada)

10.30 a.m. Coffee Break - Visit of the exhibition and poster areas (Pavilion 4, level 1)

11.00 a.m.

11.00 a.m. SYMPOSIUM SPONSORED BY BAYER PHARMACEUTICALS

12.30 p.m. In May 2007, are hypertensive patients with metabolic syndrome still different fromother hypertensive patients?Chaired by: G. Assmann (Germany)

11.00 a.m. Is the MS an illness or a risk factors accumulation? ...................................................... A. Benetos (France)

11.30 a.m. The MS definition: NCEP III vs IDF criteria and implications

for the risk of myocardial infarction .................................................................................. G. Assmann (Germany)

12.00 p.m. Why and how to treat the patients with MS? ........................................................... M.-C. Aumont (France)

12.30 p.m. Buffet lunch (Pavilion 5, level 1)

02.00 p.m.

AL-10

AL-09

AL-08

AUDITORIUM I

12

Friday May 18, 2007 / Afternoon

02.00 p.m. ACADEMIC SESSION 4

03.30 p.m. Current and future treatment strategies in cardiometabolic complications Chaired by: G. Crepaldi (Italy) - M. Komajda (France)

02.00 p.m. RAS inhibition for the treatment of HTA in diabetes ................................................. M. Komajda (France)

02.30 p.m. Nuclear receptors controlling the cardiometabolic syndrome ..................................... B. Staels (France)

03.00 p.m. Endogenous mechanisms of PPAR/RXR modulation ............................................................ J. Plutzky (USA)

03.30 p.m. Coffee Break - Visit of the exhibition and poster areas (Pavilion 4, level 1)

04.00 p.m.

04.00 p.m. SYMPOSIUM SPONSORED BY NOVARTIS

05.30 p.m. Management of high risk patientsChaired by: E. Bruckert (France)

04.00 p.m. Definition of high risk patients ....................................................................................................... E. Bruckert (France)

04.20 p.m. How to calculate the cardiovascular risk of your patients? ........................ J.-M. Lablanche (France)

04.40 p.m. High risk patients: how to reach the therapeutic goals? .......................................... T. Laperche (France)

05.00 p.m. HTN: have our therapeutic concepts changed? ........................................................................ J. Amar (France)

05.20 p.m. Discussion / Round table

AL-13

AL-12

AL-11

AUDITORIUM I

14


Saturday May 19, 2007

09.20 a.m. Introduction of the symposia by Professor Jean-Charles Fruchart09.35 a.m.

09.35 a.m. FONDATION COEUR ET ARTERES – SYMPOSIUM 1

12.00 p.m. Nutrition and cardiometabolic / cardiovascular disease risksChaired by: J. M. Silva (Portugal) - G. Schwartz (USA)

09.35 a.m. Diet in the management of adult weight loss ......................................... A.Tremblay (Canada)

10.10 a.m. Do polyunsaturated fatty acid intake reduce the risk of cardiovascular diseases?

........................................................................................................................... W.S. Harris (USA)

10.45 a.m. Chronic and acute inappropriate food intake and acute coronary syndrome:

a cardiologist view ........................................................................................ N. Marx (Germany)

11.20 a.m. Relationship between non alcoholic fatty liver disease,

visceral fat and physical activity ....................................................................... R. Ross (Canada)

12.00 p.m. Buffet lunch (Pavilion 5, level 1)

02.00 p.m.

02.00 p.m. FONDATION COEUR ET ARTERES – SYMPOSIUM 2

04.00 p.m. Physical activity and cardiometabolic /cardiovascular disease risksChaired by: A.Tremblay (Canada)

02.00 p.m. Which types and which amount of physical activities to achieve and maintain

a healthy body weight? .......................................................................... P.A. McCullough (USA)

02.35 p.m. Does the regular practice of physical activity decrease cardiovascular disease risks?

.................................................................................................................... J. Gill (Scotland - UK)

03.10 p.m. Reduction of the cardiometabolic risks:how to overcome the sociological,environmental and

behavioural preventions to a regular practice of physical activities? The example of ICAPS,

a multilevel intervention program centred on adolescents’physical activity .... C. Simon (France)

02.00 p.m. PPARS WHITE PAPER (PRIVATE SESSION)

06.00 p.m.

Sunday May 20, 2007

09.00 a.m. DISCUSSED POSTER SESSION

10.30 a.m. Chaired by: J.-C. Fruchart (France)

AL-20

AL-19

AL-18

AL-17

AL-16

AL-15

AL-14

AUDITORIUM I

AUDITORIUM II

15

17

LIST OF POSTER ABSTRACTS

List of poster abstracts

P01 WAYS OF STABILIZATION OF ARTERIAL PRESSURE OF THE WOMEN IN MENOPAUSEAtahanova L.E.,Talipova Y.S., Ismailova M.S., Sagatova H.M.,

Republic of Uzbekistan, the Tashkent Doctors Postgraduate Institute.

E-mail:[email protected]

P02 ADIPOCYTE, EPIDERMAL FATTY ACID BINDING PROTEINS, PAI-1 AND OTHER MARKERS OF METABOLIC SYNDROME IN SERUM OF PATIENTS WITH DM TYPE 2 AND HEALTHY PERSONSR. Ben Yahia1, R. Lichnovska1, L. Janusova1, J. Petrek1, M. Karpisek2,3,V Krcová4, L. Slavik4, A. Hlusi3,T. Brychta5,

S. Brychtova6, J. Necas1

1 Department of Physiology, Faculty of Medicine, Palacky University, 775 15 Olomouc, Czech Republic. E-mail:

[email protected]

2 BioVendor Laboratore Brno.

3 Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical

Science, Brno.

4 Department of Hemato-Oncology University Hospital, Olomouc.

5 SPEA Olomouc.

6 Department of Pathology, Faculty of Medicine, Palacky University, 775 15 Olomouc.

P03 THE ASSOCIATION BETWEEN MEAN PLATELET VOLUME AND GLYSEMIC CONTROL IN DIABETIC PATIENTSFatma Paksoy, MD; Cemal Bes, MD; Ayda Batuan Damar, MD; Fatih Borlu, MD

III. Internal Medicine Department, Sisli Etfal Research and Training Hospital, Istanbul,Turkey

P04 DETECTION OF CIRCULATION PROBLEMS IN DIABETIC PATIENTS WITH INFRARED IMAGESFrancisco J. Sanchez-Marin, Carlos Villaseñor-Mora

Centro de Investigaciones en Optica - Leon, Gto. México.

[email protected]

P05 COMPLEX INTERVENTION PROGRAMME IN PATIENTS WITH CARDIOVASCULAR DISEASES AND TYPE 2 DIABETESPetrlova, B., Rosolova, H., , Sipova, I., Sifalda, P., Simon, J.

Center of Preventive Cardiology of the 2nd Medical Department

University Hospital in Pilsen, Czech Republic

P06 CHARACTERISTICS OF DEGENERATE CALCINOSIS OF THE HEART VALVE STRUCTURES AND THE ATHEROSCLEROSISOF THE ELDERLY AND THE SENILE AGE IN HOT CLIMATEAtahanova L.E.,Yarmukhamedova G.H.,Talipova J.S.,Tulabaeva G.M., Ismailova M.Sh, Sagatova M.

Tashkent Doctors Postgraduate Institute.

P07 THE ROLE OF CARDIOVASCULAR AUTONOMIC NEUROPATHY IN PATHOGENESIS OF ISCHEMIC CARDIAC DISEASEIN PATIENTS WITH DIABETES MELLITUS Snjezana Popovic-Pejicic, LjiljanaTodorovic-Djilas and Pavle Pantelinac

P08 IMPORTANCE OF SELENIUM IN NUTRITIONRachid Saile1, Nadia Safir1.2, Hassan Taki1, and Layachi Chabraoui2.3

1. Laboratory of research on lipoproteins and atherosclerosis, Faculty of Sciences Ben M’sik,

2. University Hassan II-Mohammedia, Casablanca, Morocco.

3. Laboratory of Biochemistry, Hôpital d’Enfants de Rabat, BP 6542 Rabat Instituts, Morocco.

4. Laboratory of Biochemistry, Faculté de Médecine et de Pharmacie, BP. 6203 Rabat Instituts, Morocco

18


P09 IS IT POSSIBLE TO IMPROVE THE CARDIOVASCULAR RISK PROFILE IN PATIENTS WITH CARDIOVASCULAR DISEASES AND TYPE 2 DIABETES BY A COMPLEX INTERVENTION?B. Petrlova, H. Rosolova, I. Sipova, P. Sifalda, J. Simon

University Hospital, Pilsen, Czech Republic

P10 PHYSICAL CAPACITY IN OBESE CORONARY PATIENTS ADMITTED IN CARDIAC REHABILITATION COMPARISON WITH NORMAL WEIGHT CORONARY PATIENTSPh Blanc1, A Boussuges2, A Ali Benyouma1, D Bastien1, AL Diquelou1, S Chopra1.

1 Sainte Clotilde Cardiac Rehabilitation Center, Sainte Clotilde, Reunion Island

2 Mediterranean University, Marseilles, France.

P11 DIETARY INTERVENTIONS FOR THE MANAGEMENT OF ELEVATED BLOOD PRESSURE AND OTHER METABOLIC RISK FACTORS IN PATIENTS WITH METABOLIC SYNDROME – NEW ROLE FOR CLA?Bell D1, Fieliz K2,3,Weidner C1, HelwigU2, Pfeuffer M2,Winkler P3, Laue C3, Schrezenmeir J2

1 Cognis Germany GmbH & Co. KG, Monheim, Germany, 2 Institute of Physiology of Nutrition, Federal Research Centre for

Nutrition and Food (BfEL), Kiel, Germany, 3 Center of Clinical Research, tecura GmbH Medizin & Biotechnik, Kiel, Germany, 4

Institute for Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf,

Hamburg, Germany

P12 LIFESTYLE CHANGES FOR HYPERCHOLESTEROLEMIC PATIENTS WITH THE METABOLIC SYNDROME - PLANT STEROL ESTER CAPSULES PROVIDE ADDITIONAL BENEFITSWeidner C.1, Acuff R.2, Cai D.3, , Bell D.1

1 Cognis Deutschland GmbH & Co. KG, Rheinpromenade 1, 40789 Monheim, Germany

2 East Tennessee State University, College of Medicine, Johnson City,TN, USA

3 Cognis Nutrition and Health, 5325 S. Ninth Avenue, La Grange, IL 60525, USA

P13 EFFECT OF FOOD MATRICES ON UPTAKE CHARACTERISTICS OF CONJUGATED LINOLEIC ACIDD. Bell1, S. Spät1, C. Schulz2,

1 Cognis Deutschland GmbH & Co. KG, Rheinpromenade 1, D-40789 Monheim

2 BioTeSys GmbH, Schelztorstr. 54-56, D-73728 Esslingen

P14 RECENT ADVANCES IN NUTRACEUTICAL RESEARCH: HOW TO MANAGE SUSTAINABLE BODY FAT LOSS AND REDUCE INFLAMMATION OF ADIPOSE TISSUEBell, D.1, Spät S.1,Theisen A.2

1 Cognis Deutschland GmbH & Co. KG, Nutrition & Health, Global R&D, Rheinpromenade 1 - 40789 Monheim/Germany

2 Theisanet Consulting, Hachhauser Str. 51, 45711 Datteln/Germany

P15 VALIDITY OF THE ATP III DIAGNOSTIC CRITERIA FOR THE METABOLIC SYNDROME IN AN ELDERLY ITALIANCAUCASIAN POPULATION. THE ITALIAN LONGITUDINAL STUDY ON AGINGS.Maggi, M.Noale, G. Crepaldi

National Research Council, Aging Branch, Institute of Neuroscience, Padova, Italy

19

Information to the faculty and poster authors

YOU ARE A CHAIRMAN

We thank you for proceeding to the CONFERENCE ROOM (Auditorium 1) at least 15 minutes prior to the

beginning of the session you are chairing.

Speakers have to comply with the speaking time which has been allotted to them.

We thank you in advance for seeing to this parameter.

YOU ARE A SPEAKER

We thank you for proceeding to the PREVIEW ROOM / SLIDE CENTER (Room 1.13) at least 30 minutes

prior to the beginning of the session in which you will give a lecture.

Thank you for conforming to the instructions given by the chairpersons of your session.

PREVIEWING YOUR ORAL PRESENTATION

PREVIEW ROOM / SLIDE CENTER (Room 1.13) located level 1

A computer expert will welcome you in the PREVIEW ROOM / SLIDE CENTER according tothe following schedule:

Wednesday May 16th 4.00 - 6.00 p.m.




(closing between 12.30 p.m. and 01.30 p.m. for lunch)

20


YOU ARE A POSTER AUTHOR

Posters will be displayed for the whole length of the congress in the Pavilion 4 located on the level 1

right in the middle of the exhibition area.

Fixing materials will be available at the congress welcome desk located in the Foyer C and in the

Pavilion 4.

Poster authors are kindly requested to comply with the following schedule for mounting and removing

their posters:

MountingFrom 4.00 to 7.00 p.m. on Wednesday May 16th

As from 8.30 a.m. on Thursday May 17th

We thank you for standing close to your poster during coffee breaks in order to discuss your work with

delegates. Here is the schedule of the different coffee breaks:

Thursday May 17th 10.15 a.m. - 10.45 a.m. and 3.30 p.m. - 4.00 p.m.

Friday May 18th 10.30 a.m. - 11.00 a.m. and 3.30 p.m. - 4.00 p.m.

Saturday May 19th 10.30 a.m. - 11.00 a.m. and 3.00 p.m. - 3.30 p.m.

RemovalAs from 5.00 p.m. on Saturday May 19th

ABSTRACT CODIFICATION (ORAL AND POSTER COMMUNICATIONS)Abstracts related to the oral communications begin with « AL ».

“AL” stands for Academic Lecture (i.e. a lecture given within an Academic Session).

The last two digits correspond to the abstract number.

Abstracts related to the poster communications begin with a « P » + abstract number.

21

General information

DATES AND CONGRESS VENUE

The congress will take place in Lisbon (Portugal) from Wednesday May 16th through Sunday May 20th 2007.

Lisbon Congress Centre / Centro de Congressos de LisboaPraça das Indústrias - 1300-307 Lisboa (Portugal)

Phone: (+351) (0)213 652 000 - Fax: (+351) (0)213 639 450

Web site: www.lisboacc.pt

Opening hours of the congress welcome deskMain entrance of the Lisbon Congress Centre / Level 1

Wednesday May 16th 04.00 p.m. - 07.00 p.m.




SCIENTIFIC COMMITTEE

Chair: Pr Jean-Charles FRUCHART

Atherosclerosis Department and UR 545 Inserm

Pasteur Institute (Lille)

1, rue du Professeur Calmette - 59019 Lille Cedex (France)

Phone: (+33) (0)3 20 87 73 56 - Fax: (+33) (0)3 20 87 73 19 or 60

Members: Dr Jamila FRUCHART-NAJIB, Pr Patrick DURIEZ, Pr Bart STAELS

ORGANIZING SECRETARIAT

During the congressLisbon Congress Centre – Foyer C, Level 0 – Congress welcome desk

After the congressMSDA 2007 c/o PLB. OrganisationHôtel de Créquy - 15 rue de Pontoise - 78100 Saint-Germain-en-Laye (France)

Phone: (+33) (0)1 39 04 24 24 - Fax: (+33) (0)1 39 04 24 77

Email: [email protected]

Managing Director: Mr Pascal LE BORGNE

Congress managers: Mr Fabien DUVAL-ALEXANDRE, Mrs Nathalie MARTAIN

On site registration fees• PARTICIPANT 600 €

• STUDENT 300 €

22


The registration fees to the congress include the congress documents (Final program andAbstract book) as well as admission to:• all congress oral and poster sessions

• the exhibition area from May 16th to May 19th

• the lunch box on May 17th and lunches on May 18th and 19th

• the coffee breaks on May 17th and 18th

• the welcome cocktail following the congress opening ceremony on Wednesday May 16th at the

restaurant of the Lisbon Congress Centre (Espaço Tejo, level 1)

Websitewww.msdacongress.com

OFFICIAL CARRIER

Reference to be quoted: SE7200

Validity from 11/05/2007 to 25/05/2007

On international routesDiscount registered under GGAIRAFEVENTNEGO

On presentation of the original of this document AIR FRANCE offices throughout the World will offer you

preferential fares (subject to conditions) from your country of departure # on the regular full fare in

business or economy class for your round-trip journey to attend this event.

Your nearest Air France office:

www.airfrance.com

On the domestic network within metropolitan FranceDiscount registered under GGAIRAFGLOBALMEETINGS

This original document will entitle you to a rebate of up to 45% (subject to conditions) on the regular

full fare in economy class for your round-trip journey on the Air France metropolitan domestic network

to attend this event.

To book and obtain your electronic ticket within France, contact 3654* or your travel agent in

metropolitan France or your Air France office.

Your nearest Air France office:

www.airfrance.com

* charge for calls: 0,34 /min

23

Congress from A to Z

ABSTRACT BOOK

This book is available to all registered delegates.

Abstracts have been coded as follows:

• AL (Academic Lectures - Academic Sessions)

• P (Poster Communications)

BADGES

All participants are kindly requested to wear badge at all times throughout the congress and during social events.

BLUE for DELEGATES GREEN for EXHIBITORS

RED for FACULTY (speakers and chairpersons) YELLOW for ORGANIZATION

CERTIFICATE OF ATTENDANCE

Each registered participant will find the corresponding certificate of attendance in the congress kit at the congress welcome desk.

COFFEE BREAKS – PAVILION 4 - LEVEL 1They will be served to all registered participants during the following schedule:

Thursday May 17th from 10.15 to 10.45 a.m. and from 03.30 p.m. to 04.00 p.m.

Friday May 18th from 10.30 to 11.00 a.m. and from 03.30 p.m. to 04.00 p.m.

Saturday May 19th from 10.30 to 11.00 a.m. and from 03.00 p.m. to 03.30 p.m.

EXHIBITION – PAVILION 4 - LEVEL 1Opening hours of the exhibition

Wednesday May 16th 4.00 - 7.00 p.m Friday May 18th 8.30 a.m. - 6.00 p.m.

Thursday May 17th 8.30 a.m. - 6.00 p.m. Saturday May 19th 8.30 a.m. - 5.00 p.m.

HOTELS

The organizing secretariat has arranged accommodation on request for groups in the following hotels

(listed in alphabetical order):

CORINTHIA – av. Columbano Bordalo Pinheiro 105 - Phone + 351 21 723 63 00 - Fax + 351 21 723 63 66

DOM PEDRO – av. Eng° Duarte Pacheco 24 - Phone + 351 21 389 66 00- Fax + 351 21 389 66 01

MERIDIEN PARK ATLANTIC – rua Castilho 149 - Phone + 351 21 381 87 00 - Fax + 351 21 389 05 00

PESTANA PALACE – rua Jau 54 - Phone + 351 21 361 56 15 - Fax + 351 21 361 56 25

SOFITEL – av. da Liberdade, 127 - Phone + 351 21 322 83 00 - Fax + 351 21 322 83 10

INSURANCE

The organizers cannot be held liable for medical, travel or personal claims.

Participants are strongly advised to seek personal insurance coverage.

LECTURES

Please note that lectures have been coded as follows:

• AL (Academic Lectures - Academic Sessions)

24


LUNCHES - PAVILION 5 - LEVEL 1The lunches on May 17th, 18th and 19th are included in the registration fees.

On Thursday May 17th, lunch boxes will be served in the:• AUDITORIUM 1 (lunch debate AstraZeneca) / Level 1: 12.45 - 02.15 p.m.

On Friday May 18th and Saturday May 19th, lunches will be served in the:• PAVILION 5 – LISBON CONGRESS CENTRE / Level 1: 12.30 - 02.00 p.m.

MESSAGES

Should you wish to leave a message to another participant, please report to the congress welcome desk.

Please regularly consult the message board located near the congress welcome desk.

NO SMOKING

Please remember that smoking is prohibited within the Auditoria as well as in the poster, exhibition and lunch areas.

OFFICIAL LANGUAGE

The official language of the congress is English.

Academic sessions, symposia and lunch debates will be simultaneously translated into French.

OPENING CEREMONY & WELCOME COCKTAIL

All registered delegates are invited to attend the congress opening ceremony to be held on Wednesday, May 16th, 2007

from 7.00 to 7.30 p.m. in the auditorium 1, level 1.

A welcome cocktail will be served at the end of this session from 7.30 to 9.00 p.m at the Restaurant “Espaço Tejo”, level 1.

POSTER DISPLAY – PAVILION 4 - LEVEL 1Posters are displayed for the whole duration of the congress. They must be set up in the poster display located level 1

(Pavilion 4). Please set up your poster according to the poster number you have been given (refer to the list in the poster dis-

play area). Hanging fixtures are available in this area and at the congress welcome desk. Authors are requested to mount their

poster between 4.00 and 7.00 p.m. on Wednesday May 16th and as from 8.30 am on Thursday May 17th, 2007.

Opening hours of the poster exhibitionThursday May 17th 8.30 a.m. - 6.00 p.m. Saturday May 19th 8.30 a.m. - 5.00 p.m.


PREVIEW ROOM / SLIDE CENTER – ROOM 1.13 - LEVEL 1In order to insure the easy running of the congress, all speakers must proceed to the Preview room / Slide center in advance in

order to have their oral presentation loaded. A computer technician will be in the Preview room / Slide center (Room 1.13,

level 1) according to the following schedule:

Wednesday May 16th 4.00 p.m. - 6.00 p.m. Friday May 18th 8.00 a.m. - 6.00 p.m.

Thursday May 17th 8.00 a.m. - 6.00 p.m. Saturday May 19th 8.30 a.m. - 5.00 p.m.

(closing between 12.30 p.m. and 01.30 p.m. for lunch)

TOURIST OFFICE IN LISBON

For further information regarding sightseeing tours and places of interest please contact the Lisbon Tourist Office at:

Address: rua do Arsenal, 15 1100-038 Lisboa - Portugal

Phone: +351 210 312 810

Fax: +351 210 312 819

25

Metabolic Syndrome, type ll Diabetesand Atherosclerosis congress 5th

2008

ORGANIZING SECRETARIATMSDA 2008 c/o PLB. Organisation

Hôtel de Créquy - 15 rue de Pontoise - 78100 Saint-Germain-en-Laye (France)Phone: (+33) (0)1 39 04 24 24 - Fax: (+33) (0)1 39 04 24 77

Email: [email protected]

Notes

Notes

Documents

Under the aegis of - MSDA Congress · W.S.Harris (USA) N.Marx (Germany) R.Ross (Canada) BUFFET LUNCH FONDATION CŒUR ET ARTÈRES SYMPOSIUM 2 Physical activity and cardiometabolic